ArticleMaterials today. Bio2025
4D-printed hydrogel with precise regulation of viability and environment of stem cells for diabetic skin wound healing.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Adipose-derived extracellular vesicles miR-423-5p targets SMAD3 to reverse endometrial fibrosis in a porcine model of intrauterine adhesion: insights from single-cell sequencing.Materials today. Bio · 2026Article
- From Smart Hydrogel Design to 4D-Printed Scaffolds: Emerging Paradigms in Precision Drug Delivery and Regenerative Wound Therapy.Gels (Basel, Switzerland) · 2026Review
- 4D morphogenetic tissue engineering via gradient-crosslinked microporous hydrogel scaffolds.Materials today. Bio · 2026Article
- The Role of 3D Printing in Regenerative Medicine: A Game-Changer in Tissue Engineering.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic wounds not only suffer from vascular and nerve damage, but also face the severe challenge of impaired stem cell activity. In recent years, although traditional tissue engineering strategies provide exogenous stem cells for the healing of diabetic wounds, they have not reversed the dilemma of stem cell proliferation and differentiation in a high-glucose environment. In this work, piRNA-hsa-32182 was first demonstrated to be highly expressed in diabetic wounds and significantly inhibit the differentiation and migration of adipose-derived mesenchymal stem cells (ADMSCs). Accordingly, a 4D-printed tissue engineering hydrogel and piRNA-hsa-32182 antagomir were prepared to precisely modulate the survival microenvironment of ADMSCs and accelerate diabetic wound healing. 4D printed tissue engineering hydrogels provided a highly ordered microenvironment for ADMSCs through internal space homogenization, thereby effectively improving the loading rate and survival rate of stem cells. In addition, piRNA-hsa-32182 antagomir effectively enhanced the migration of ADMSCs, thereby increasing the deposition and maturation of collagen on the wound and promoting angiogenesis. In summary, this study significantly improved the microenvironment of wounds through the synergy of bio-intelligent printing technology and gene expression regulation, providing a new clinical paradigm for the treatment of diabetic wounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.